United Therapeutics CEO trust sells 9,500 shares
The plan continues until the earlier of exercise of 1,734,410 stock options or December 31, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
United Therapeutics (UTHR) Chairperson & CEO Martine A. Rothblatt reported that a family trust exercised 9,500 stock options on November 3, 2026, at an exercise price of $117.76 per share, then sold the resulting 9,500 common shares in multiple trades. The reported weighted-average prices for the sale transactions ranged from $598.6760 to $605.9700 per share. The transactions were pursuant to a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025. The trust’s reported post-exercise position was 100,410 stock options.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option F1, F14, F15 | 9,500 | $0.00 | $0.00 |
| Exercise | Common Stock F1, F2 | 9,500 | $117.76 | $1.12M |
| Sale | Common Stock F1, F3, F2 | 426 | $598.676 | $255K |
| Sale | Common Stock F1, F4, F2 | 1,284 | $599.8017 | $770K |
| Sale | Common Stock F1, F5, F2 | 2,202 | $600.7279 | $1.32M |
| Sale | Common Stock F1, F6, F2 | 1,440 | $601.5371 | $866K |
| Sale | Common Stock F1, F7, F2 | 1,261 | $602.7885 | $760K |
| Sale | Common Stock F1, F8, F2 | 1,927 | $603.6983 | $1.16M |
| Sale | Common Stock F1, F9, F2 | 840 | $604.6513 | $508K |
| Sale | Common Stock F1, F10, F2 | 120 | $605.97 | $73K |
| Holding | Common Stock | -- | -- | -- |
| Holding | Common Stock | -- | -- | -- |
| Holding | Common Stock F11 | -- | -- | -- |
| Holding | Common Stock F12 | -- | -- | -- |
| Holding | Common Stock F13 | -- | -- | -- |
Footnotes (15)
- F1. This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
- F10. This transaction was executed in multiple trades at prices ranging from $605.78 to $606.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F11. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F12. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F13. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F14. These stock options vested in equal one-third installments on March 15, 2021, 2022 and 2023.
- F15. Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
- F2. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F3. This transaction was executed in multiple trades at prices ranging from $598.10 to $599.08. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $599.18 to $600.15. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $600.20 to $601.18. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $601.215 to $602.17. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $602.29 to $603.275. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8. This transaction was executed in multiple trades at prices ranging from $603.29 to $604.27. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9. This transaction was executed in multiple trades at prices ranging from $604.34 to $605.18. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Key Terms
pre-arranged 10b5-1 trading plan regulatory
weighted average price financial
stock options financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many UTHR stock options were exercised, and what was the exercise price?
AI-generated analysis. How Rhea-AI works. Not financial advice.